AHRQ Intent To Publish Grant and Contract Solicitations for Comparative Effectiveness Research (CER) Projects With Funds From the American Recovery and Reinvestment Act (ARRA), 41913-41914 [E9-19758]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 159 / Wednesday, August 19, 2009 / Notices
the agreement and proposed order or to
modify in any way their terms.
By direction of the Commission.
Richard C. Donohue
Acting Secretary.
[FR Doc. E9–19810 Filed 8–18–09; 1:13 pm]
BILLING CODE 6750–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–09–0008]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Maryam Daneshvar,
CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS–D74,
Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
41913
transmission, and to help identify the
cause of an outbreak. The EPI–AID
mechanism is a means for Epidemic
Intelligence Service (EIS) officers of the
Centers for Disease Control and
Prevention (CDC), along with other CDC
staff, to provide technical support to
State health agencies requesting
assistance with epidemiologic field
investigations. This mechanism allows
CDC to respond rapidly to public health
problems in need of urgent attention,
thereby providing an important service
to State and other public health
agencies. Through EPI–AIDS, EIS
officers (and, sometimes, other CDC
trainees) receive supervised training
while actively participating in
epidemiologic investigations. EIS is a
two-year program of training and service
in applied epidemiology through CDC,
primarily for persons holding doctoral
degrees.
Shortly after completion of the EPI–
AID investigation, an Epi Trip Report is
delivered to the State health agency
official(s) who requested assistance.
These officials can comment on both the
timeliness and the practical utility of
the recommendations from the
investigation by completing a brief
questionnaire to assess the promptness
of the investigation and the usefulness
of the recommendations. There is no
cost to the respondents other than their
time.
Proposed Project
Emergency Epidemic Investigations—
Extension—(0920–0008), Office of
Workforce and Career Development
(OWCD), Centers for Disease Control
and Prevention (CDC).
Background & Brief Description
The purpose of the Emergency
Epidemic Investigation surveillance is
to collect data on the conditions
surrounding and preceding the onset of
a problem. The data must be collected
in a timely fashion so that information
can be used to develop prevention and
control techniques, to interrupt disease
ESTIMATED ANNUALIZED BURDEN HOURS
Respondents
Number of
respondents
(per year)
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total burden
(in hours)
Requestors of EPI–AIDs ..................................................................................
100
1
15/60
25
Dated: August 10, 2009.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E9–19836 Filed 8–18–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
AHRQ Intent To Publish Grant and
Contract Solicitations for Comparative
Effectiveness Research (CER) Projects
With Funds From the American
Recovery and Reinvestment Act
(ARRA)
Agency for Healthcare Research and
Quality
jlentini on DSKJ8SOYB1PROD with NOTICES
AGENCY: Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION:
Notice of Intent.
SUMMARY: AHRQ is announcing the
Agency’s intention to support new CER
projects, with funding from the
American Recovery and Reinvestment
Act (ARRA). The ARRA appropriated
VerDate Nov<24>2008
19:20 Aug 18, 2009
Jkt 217001
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
$300 million to AHRQ for support of
CER. ARRA funding will focus, initially,
on 14 priority conditions established by
the Secretary of the Department of
Health and Human Services under
Section 1013 of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003. These
priority conditions were identified
through a process involving discussion
with, and extensive input from, the
public as well as Federal agencies. The
list of priority conditions is relevant to
the Medicare, Medicaid, and State
Children’s Health Insurance Program
(SCHIP) programs, and can be found at:
https://effectivehealthcare.ahrq.gov/
aboutUs.cfm?abouttype=program
#Conditions.
DATES: AHRQ anticipates grant and
contract solicitations to be published
E:\FR\FM\19AUN1.SGM
19AUN1
41914
Federal Register / Vol. 74, No. 159 / Wednesday, August 19, 2009 / Notices
beginning in the fall, 2009, with funding
to commence in spring, 2010. Interested
parties may sign up to receive updates
about AHRQ’s Effective Health Care
Program at https://
effectivehealthcare.ahrq.gov/.
ADDRESSES: The future CER solicitations
will be published in the NIH Guide:
https://grants.nih.gov/grants/guide/
index.html.
FOR FURTHER INFORMATION CONTACT:
Until the solicitations are published,
AHRQ cannot provide information on
their contents.
Direct any general comments
regarding the Effective Health Care
program to: Lia Hotchkiss, MPH, PMP,
Center for Outcomes and Evidence,
Agency for Healthcare Research and
Quality, 540 Gaither Road, Rockville,
MD 20850, Telephone: 301–427–1502,
E-mail address:
Effectivehealthcare@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
jlentini on DSKJ8SOYB1PROD with NOTICES
Background
The Agency for Healthcare Research
and Quality (AHRQ) has been
supporting comparative effectiveness
research for many years and since 2005
through AHRQ’s Effective Health Care
Program, which was authorized under
Section 1013 of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003. The
Effective Health Care program provides
systematic reviews and develops other
translational information and tools
designed to inform health care decision
making. The Effective Health Care
Program advances the methodology of
comparative effectiveness research
(CER) and provides training grants to
enhance the pool of researchers who can
perform CER.
Comparative Effectiveness Research
Initiative Description
Funding Opportunity
Announcements soliciting research
grant applications for CER will provide
$148 million for evidence generation.
This includes $100 million for the
Clinical and Health Outcomes Initiative
in Comparative Effectiveness (CHOICE),
a new, coordinated, national effort to
establish a series of prospective
pragmatic clinical comparative
effectiveness studies that measure the
benefits treatments produce in routine
clinical practice and will include novel
study designs focusing on real-world
and under-represented populations
(children, elderly, racial and ethnic
minorities, and other understudied
populations), and $48 million for the
establishment or enhancement of
national patient registries that can be
VerDate Nov<24>2008
16:53 Aug 18, 2009
Jkt 217001
used for researching the longitudinal
effects of different interventions and
collecting data on under-represented
populations. Additional grant funding is
expected to include $29.5 million to
support innovative translation and
dissemination grants related to CER, as
well as $20 million to support training
and career development in CER.
Requests for Contracts for CER will
provide $9.5 million to establish an
infrastructure to identify new and/or
emerging issues for comparative
effectiveness review investments. Also,
$10 million will establish a Citizen’s
Forum to formally engage all
stakeholders, and to expand and
standardize public involvement in the
entire Effective Health Care enterprise.
Additionally, AHRQ anticipates
supporting other grants ($1 million) and
enhancing existing contracts for
evidence synthesis ($50 million),
evidence generation ($24 million),
translation and dissemination ($5
million), and salary and benefits for
ARRA-related full-time equivalent
positions ($3 million).
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: D. G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 11, 2009.
Carolyn M. Clancy,
AHRQ, Director.
[FR Doc. E9–19758 Filed 8–18–09; 8:45 am]
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; P01 Application.
Date: October 28, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Dated: August 11, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–19889 Filed 8–18–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Name of Committee: Recombinant DNA
Advisory Committee.
Date: September 9–10, 2009.
Time: September 9, 2009, 1:15 p.m. to 5:45
p.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols as well as
related data management activities. Please
check the meeting agenda at https://
oba.od.nih.gov/rdna/rdna.html for more
information.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Time: September 10, 2009, 8:30 a.m. to 11
a.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols as well as
related data management activities. Please
check the meeting agenda at https://
oba.od.nih.gov/rdna/rdna.html for more
information.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Laurie Lewallen, Advisory
Committee Coordinator, Office of
Biotechnology Activities, National Institutes
of Health, 6705 Rockledge Drive, Room 750,
E:\FR\FM\19AUN1.SGM
19AUN1
]]>Agencies
[Federal Register Volume 74, Number 159 (Wednesday, August 19, 2009)]
[Notices]
[Pages 41913-41914]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-19758]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
AHRQ Intent To Publish Grant and Contract Solicitations for
Comparative Effectiveness Research (CER) Projects With Funds From the
American Recovery and Reinvestment Act (ARRA)
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Notice of Intent.
-----------------------------------------------------------------------
SUMMARY: AHRQ is announcing the Agency's intention to support new CER
projects, with funding from the American Recovery and Reinvestment Act
(ARRA). The ARRA appropriated $300 million to AHRQ for support of CER.
ARRA funding will focus, initially, on 14 priority conditions
established by the Secretary of the Department of Health and Human
Services under Section 1013 of the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003. These priority conditions
were identified through a process involving discussion with, and
extensive input from, the public as well as Federal agencies. The list
of priority conditions is relevant to the Medicare, Medicaid, and State
Children's Health Insurance Program (SCHIP) programs, and can be found
at: https://effectivehealthcare.ahrq.gov/aboutUs.cfm?abouttype=program#Conditions.
DATES: AHRQ anticipates grant and contract solicitations to be
published
[[Page 41914]]
beginning in the fall, 2009, with funding to commence in spring, 2010.
Interested parties may sign up to receive updates about AHRQ's
Effective Health Care Program at https://effectivehealthcare.ahrq.gov/.
ADDRESSES: The future CER solicitations will be published in the NIH
Guide: https://grants.nih.gov/grants/guide/.
FOR FURTHER INFORMATION CONTACT: Until the solicitations are published,
AHRQ cannot provide information on their contents.
Direct any general comments regarding the Effective Health Care
program to: Lia Hotchkiss, MPH, PMP, Center for Outcomes and Evidence,
Agency for Healthcare Research and Quality, 540 Gaither Road,
Rockville, MD 20850, Telephone: 301-427-1502, E-mail address:
Effectivehealthcare@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
Background
The Agency for Healthcare Research and Quality (AHRQ) has been
supporting comparative effectiveness research for many years and since
2005 through AHRQ's Effective Health Care Program, which was authorized
under Section 1013 of the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003. The Effective Health Care program provides
systematic reviews and develops other translational information and
tools designed to inform health care decision making. The Effective
Health Care Program advances the methodology of comparative
effectiveness research (CER) and provides training grants to enhance
the pool of researchers who can perform CER.
Comparative Effectiveness Research Initiative Description
Funding Opportunity Announcements soliciting research grant
applications for CER will provide $148 million for evidence generation.
This includes $100 million for the Clinical and Health Outcomes
Initiative in Comparative Effectiveness (CHOICE), a new, coordinated,
national effort to establish a series of prospective pragmatic clinical
comparative effectiveness studies that measure the benefits treatments
produce in routine clinical practice and will include novel study
designs focusing on real-world and under-represented populations
(children, elderly, racial and ethnic minorities, and other
understudied populations), and $48 million for the establishment or
enhancement of national patient registries that can be used for
researching the longitudinal effects of different interventions and
collecting data on under-represented populations. Additional grant
funding is expected to include $29.5 million to support innovative
translation and dissemination grants related to CER, as well as $20
million to support training and career development in CER.
Requests for Contracts for CER will provide $9.5 million to
establish an infrastructure to identify new and/or emerging issues for
comparative effectiveness review investments. Also, $10 million will
establish a Citizen's Forum to formally engage all stakeholders, and to
expand and standardize public involvement in the entire Effective
Health Care enterprise.
Additionally, AHRQ anticipates supporting other grants ($1 million)
and enhancing existing contracts for evidence synthesis ($50 million),
evidence generation ($24 million), translation and dissemination ($5
million), and salary and benefits for ARRA-related full-time equivalent
positions ($3 million).
Dated: August 11, 2009.
Carolyn M. Clancy,
AHRQ, Director.
[FR Doc. E9-19758 Filed 8-18-09; 8:45 am]
BILLING CODE 4160-90-M
